Eli Lilly looks to extend its winning streak over the broader market to 6 years
The drugmaker's ability to further expand available supply of its obesity and weight loss drugs is crucial.
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024.
Shelby Knowles | Bloomberg | Getty Images
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street woke up to its massive opportunity in obesity drugs. Six in a row is not out of the question.